Longer time to first intravitreal aflibercept injection affects outcomes in MEfCRVO

Patients with macular edema due to central retinal vein occlusion (MEfCRVO) who did not receive their first intravitreal aflibercept injection (IAI) until >3 months after diagnosis had worse visual improvement compared to patients who received their first IAI <1 month after diagnosis, according to a presentation at ASRS 2022. Greater...